EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of advanced non small cell lung carcinoma with taxotere, Gemcitabine and G-CSF



Treatment of advanced non small cell lung carcinoma with taxotere, Gemcitabine and G-CSF



British Journal of Cancer 80(SUPPL 2): 105, July




(PDF 0-2 workdays service: $29.90)

Accession: 035980868

Download citation: RISBibTeXText



Related references

Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results. Seminars in Oncology 24(4 Suppl 14): S14-22-S14-25, 1997

Cisplatin-carboplatin-gemcitabine or ifosfamide-gemcitabine in advanced non-small cell lung carcinoma: two pilot studies. Anticancer Research 19(6c): 5651-5655, 2000

A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer ChemoTherapy and Pharmacology 64(2): 379-384, 2009

A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non-small cell lung carcinoma: a phase II study. Cancer Research and Treatment 36(1): 62-67, 2004

Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC). Ai Zheng 23(11 Suppl): 1455-1458, 2004

Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 23(16_suppl): 7329-7329, 2016

Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 5(6): 427-428, 2002

Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial. Chinese Journal of Cancer Research 24(2): 97-102, 2013

Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. Journal of Thoracic Oncology 9(5): 733-737, 2015

Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. Journal of Clinical Oncology 23(33): 8380-8388, 2005

Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer. Oncology 68(4-6): 485-492, 2005

Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma. Lung Cancer 60(1): 83-91, 2007

Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma. Seminars in Oncology 24(3 Suppl 8): S8-18-S8-23, 1997

Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma. Lung Cancer 32(2): 189-196, 2001

Assessment and Validation of Syndromic Case definitions for Respiratory Syncytial Virus Testing in a Low Resource Population. Pediatric Infectious Disease Journal, 2018